31-Aug-2026
TipRanks (Thu, 27-Aug 7:40 AM ET)
Market Chameleon (Wed, 26-Aug 7:44 AM ET)
Globe Newswire (Tue, 25-Aug 10:23 AM ET)
Zymeworks Announces Participation in Upcoming Investor Conferences
Globe Newswire (Tue, 11-Aug 6:00 AM ET)
Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Globe Newswire (Thu, 6-Aug 4:05 PM ET)
Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026
Globe Newswire (Thu, 16-Jul 6:00 AM ET)
PRNewswire (Mon, 6-Jul 11:20 AM ET)
Zymeworks to Acquire Theravance Biopharma, Inc.
Globe Newswire (Mon, 29-Jun 6:00 AM ET)
Gandeeva and Zymeworks Use Cryo-EM to Accelerate Antibody Drug Discovery
PRNewswire (Thu, 18-Jun 8:00 AM ET)
Globe Newswire (Sun, 14-Jun 6:05 PM ET)
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Zymeworks trades on the NASDAQ stock market under the symbol ZYME.
As of August 31, 2026, ZYME stock price climbed to $29.41 with 666,220 million shares trading.
ZYME has a beta of 0.13, meaning it tends to be less sensitive to market movements. ZYME has a correlation of 0.00 to the broad based SPY ETF.
ZYME has a market cap of $2.10 billion. This is considered a Mid Cap stock.
Last quarter Zymeworks reported $5 million in Revenue and -$.62 earnings per share. This fell short of revenue expectation by $-14 million and missed earnings estimates by -$.22.
In the last 3 years, ZYME traded as high as $30.62 and as low as $6.02.
The top ETF exchange traded funds that ZYME belongs to (by Net Assets): IWM, VTI, IBB, IWO, VTWO.
ZYME has outperformed the market in the last year with a price return of +98.2% while the SPY ETF gained +19.4%. ZYME has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +15.4% and +17.1%, respectively, while the SPY returned +1.9% and -1.2%, respectively.
ZYME support price is $27.27 and resistance is $29.27 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ZYME shares will trade within this expected range on the day.